Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacira Pharmaceuticals, Inc. on December 9, 2011, covering events occurring on December 8, 2011. The filing addresses an amendment to a services agreement with key personnel.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific contractual compensation fees.
Material Changes
The Company entered into an Amendment to Services Agreement with MPM Asset Management LLC and Gary Patou. This amendment reversed a previously planned reduction in consulting time and fees:
- Consulting Time: Reverted from a planned 50% allocation in 2012 back to 80% through September 30, 2012.
- Monthly Fee: Reverted from a planned reduction to $15,880.40 back to $26,467.33 through September 30, 2012.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the amended agreement. The filing notes that after September 30, 2012, services will revert to the terms of the existing Services Agreement. No specific guidance, risks, or contingencies regarding the Company's broader business outlook are detailed in this report.
Investor Verification Checklist
- Verify the full text of the Amended Services Agreement (Exhibit 10.1) for additional terms or conditions.
- Confirm the impact of the increased consulting fees on the Company's operating expenses for the remainder of 2012.
- Review the original Services Agreement to understand the terms applicable after September 30, 2012.